ChromaDex (CDXC) Reports Promising Findings from a Clinical Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Aligarh : Subject experts discussed trends in nanotechnology and their mass applications that are likely to have great impact in industry, medicine, new computing systems and sustainability in the first colloquium of the International web confe
COVID-19 Collection thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Analysis of 10 studies shows ivermectin not effective in treating COVID-19
A new meta-analysis of 10 studies shows ivermectin (IVM), an anti-parasite drug, is not an effective treatment for COVID-19 and is not a viable treatment option for patients. The study was published yesterday in
Clinical Infectious Diseases.
The authors analyzed results from 10 randomized control trials (RCTs) that included 1,173 patients total, and looked for IVM s effect on all-cause mortality, length of hospital stay, adverse events, and viral clearance compared to standard of care.
COVID-19 patients had mild disease in 8 of the trials, moderate in 1 trail, and mild to moderate in 1 trial.
IVM did not reduce all-cause mortality when compared to controls (relative risk, 0.37; 95% confidence interval [CI], 0.12 to 1.13) or length of stay versus controls (0.72 days, 95% CI, −0.86 to 2.29). Adverse events, severe adverse events, and viral clearance were similar between IVM and controls, the authors foun
Metabolic activators can reduce recovery time in patients with mild-to-moderate Covid-19
Metabolic activators were found to reduce recovery time by as many as 3.5 days in patients with mild-to-moderate Covid-19, according to a Swedish-British study published today in
Advanced Science.
The researchers also found that treatment with the metabolic activators improved liver health and decreased the levels of inflammation, as shown by inflammatory markers.
Conducted by researchers at Science for Life Laboratory at KTH Royal Institute of Technology in Stockholm, in collaboration with the Sahlgrenska Academy in Gothenburg and King s College, London, the human phase three clinical study showed that patients with mild-to-moderate Covid-19 who were also receiving standard care experienced a 3.5 day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four activators